Australia markets open in 7 hours 14 minutes
  • ALL ORDS

    7,248.10
    -193.40 (-2.60%)
     
  • AUD/USD

    0.7162
    +0.0007 (+0.10%)
     
  • ASX 200

    6,961.60
    -177.90 (-2.49%)
     
  • OIL

    87.09
    +1.49 (+1.74%)
     
  • GOLD

    1,834.10
    -18.40 (-0.99%)
     
  • BTC-AUD

    53,128.25
    +1,765.36 (+3.44%)
     
  • CMC Crypto 200

    875.03
    +19.21 (+2.25%)
     

Inhalation Sedatives Global Market Research Report 2021 with Focus on Sevoflurane, Desflurane, Isoflurane, Nitrous Oxide - ResearchAndMarkets.com

·5-min read

DUBLIN, December 07, 2021--(BUSINESS WIRE)--The "Inhalation Sedatives Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global inhalation sedatives market is expected to grow from $1.28 billion in 2020 to $1.34 billion in 2021 at a compound annual growth rate (CAGR) of 4.7%. The market is expected to reach $1.62 billion in 2025 at a CAGR of 5%.

Major players in the inhalation sedatives market are AbbVie Inc., Baxter International Inc., Fresenius SE amp, Co. KgaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC., Jiangsu Hengrui Medicine Co, Lunan Pharmaceutical Group Co. Ltd, Novartis AG, Piramal Enterprises Ltd, and Troikaa Pharmaceuticals Ltd.

The inhalation sedatives market consists of sales of inhalation sedatives by companies who manufacture them. Inhalation sedatives are the drugs used to induce or maintain inhalation sedation, which is a type of conscious sedation where a drug is inhaled to suppress the central nervous system activity so that there is no much stress on the patient during a surgical process or a treatment and responds to the physician commands without protective reflexes. Inhalation sedatives are used in hospitals, ambulatory surgical centers and other care providing centers.

The inhalation sedatives market covered in this report is segmented by product into sevoflurane, desflurane, isoflurane, nitrous oxide. It is also segmented by application into induction, maintenance and by end-user into hospitals, ambulatory surgical centers, others.

Contradictions associated with inhalation sedatives are expected to hinder the market. Inhalation sedatives, although safe most of the time, can rarely result in adverse events. For instance, inhalation sedatives cannot be used in patients who have undergone a recent ear surgery as they build up pressure in the middle ear.

Also, in pregnant women, the use of inhalation sedatives is avoided to minimize the risk of possible toxicity. Inhalation sedatives affect the foetus by interfering with folic acid absorption in pregnant ladies causing neurotoxicity. Studies show that prolonged exposure to nitrous oxide may cause reproductive and haematological disorders in the operator.

The inhalation sedatives also cannot be used for patients with common cold, nasal blockage, or COPD as they cannot be absorbed by the patient, and therefore do not show the required effect. All these factors are causing a hindrance to the usage of inhalation sedatives and an acceptance of other sedative methods. Therefore, contraindications associated with inhalation sedatives are expected to hinder the market.

The short onset and duration time of inhalation sedative is expected to drive the inhalation sedative market. Rapid onset of inhalation sedative and quick recovery rate makes it applicable for short procedures especially in dental surgeries of paediatrics, and in intensive care units for decreasing the pain and quick recovery.

For instance, the most commonly used inhaled sedative is nitrous oxide, which is administered as a mixture of 30-70% of oxygen, takes about 1-2 minutes to act and the duration of action is 5 minutes. The short time required for the onset of action and its short duration makes nitrous oxide the most used inhalation sedative for dental treatment. Therefore, the short onset and duration time of inhalation sedatives is expected to drive the inhalation sedatives market.

The production of generic inhalation sedatives is expected to be the new trend in the inhalation sedatives market. Generics are a type of drug that has the same chemical formula, dosage form, dose and effect as that of the patented drug but are produced by the companies when the patent expires. The generic inhalation sedatives production has increased for the last few years. Therefore, the production of generic inhalation sedatives is expected to become the new trend in the inhalation sedatives market.

Key Topics Covered:

1. Executive Summary

2. Inhalation Sedatives Market Characteristics

3. Inhalation Sedatives Market Trends and Strategies

4. Impact Of COVID-19 On Inhalation Sedatives

5. Inhalation Sedatives Market Size and Growth

5.1. Global Inhalation Sedatives Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global Inhalation Sedatives Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Inhalation Sedatives Market Segmentation

6.1. Global Inhalation Sedatives Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Sevoflurane

  • Desflurane

  • Isoflurane

  • Nitrous Oxide

6.2. Global Inhalation Sedatives Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Induction

  • Maintenance

6.3. Global Inhalation Sedatives Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Hospitals

  • Ambulatory Surgical Centers

  • Others

7. Inhalation Sedatives Market Regional and Country Analysis

7.1. Global Inhalation Sedatives Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Inhalation Sedatives Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • AbbVie Inc.

  • Baxter International Inc.

  • Fresenius SE & Co. KgaA

  • Halocarbon Products Corporation

  • Hikma Pharmaceuticals PLC.

  • Jiangsu Hengrui Medicine Co

  • Lunan Pharmaceutical Group Co. Ltd

  • Novartis AG

  • Piramal Enterprises Ltd

  • Troikaa Pharmaceuticals Ltd

For more information about this report visit https://www.researchandmarkets.com/r/n4sukg

View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006000/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting